

Express Mail Label Number:

Please type a plus sign (+) inside this box → 

TECH CENTER 600/200  
 MAR 2 2002  
 RECEIVED  
 PTO/SB/08A (08-00)

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/028,547
				Filing Date	December 19, 2001
				First Named Inventor	Kranzler
				Group Art Unit	1614
Examiner Name	Not yet assigned				
Sheet	1	of	2	Attorney Docket Number	CYPR-023/01US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
W	P1	5,621,142		Mochizuki <i>et al</i>	04-15-1997
W	P2	4,478,836		Mouzin <i>et al</i>	10-23-1984
W	P3	5,034,541		Bigg <i>et al</i>	07-23-1991

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
W	F1		WO 01/26623		Laxdale Limited	04-19-2001	
W	F2		WO 95/22521		Asahi Kasei Kogyo Kabushiki Kaisha	08-24-1995	
W	F3		WO 97/35574		Pierre Fabre Medicament	10-02-1997	
W	F4		WO 98/08495		Pierre Fabre Medicament	03-05-1998	
W	F5		WO 98/36744		Pierre Fabre Medicament	08-27-1998	

Examiner Signature	<i>R. Corvin</i>	Date Considered	<i>8/22/02</i>
--------------------	------------------	-----------------	----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number.

<sup>2</sup> See attached Kinds of U.S. Patent Documents.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →  +



RECEIVED  
MAR 22 2002  
TECH CENTER 1600/2000  
PTO/SB/08A (08-00)

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/028,547
				Filing Date	December 19, 2001
				First Named Inventor	Kranzler
				Group Art Unit	1614
				Examiner Name	Not yet assigned
Sheet	2	of	2	Attorney Docket Number	CYPR-023/01US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
W	D1	Cypress Bioscience, Inc., Investor Fact Sheet, August 2001	
	D2	DRYSON E., Venlafaxine and fibromyalgia, <i>NZ Med J.</i> , March 10, 2000, 87, 113(1105)	
	D3	NOGUCHI et al., Open Channel Block of NMDA Receptors by Conformationally Restricted Analogs of Milnacipran and Their Protective Effect Against NMDA-Induced Neurotoxicity, <i>Synapse</i> , 1999, 87-96, 31	
	D4	SHUTO et al., (±)-(Z)-2-(Aminomethyl)-1-phenylcyclopropanecarboximide Derivatives as a New Prototype of NMDA Receptor Antagonists, <i>J. Med. Chem.</i> , 1995, 2964-2968, 38	
	D5	SHUTO et al., Synthesis and Biological Activity of Conformationally Restricted Analogs of Milnacipran: (1S,2R)-1-(Phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide, an Efficient Noncompetitive N-Methyl-D-aspartic Acid Receptor Antagonist, <i>J. Med. Chem.</i> , 1996, 4844-4852, 39	
	D6	SHUTO et al., Synthesis and Biological Activity of Conformationally Restricted Analogs of Milnacipran: (1S,2R)-1-Phenyl-2-[(R)-1-amino-2-propynyl]-N,N-diethylcyclopropanecarboximide Is a Novel Class of NMDA Receptor Channel-Blocker, <i>J. Med. Chem.</i> , 1998, 3507-3514, 41	
h	D7	SHUTO et al., (1S,2R)-1-(Phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC), a New Class of NMDA-Receptor Antagonist: Molecular Design by a Novel Conformational Restriction Strategy, <i>Jpn. J. Pharmacol.</i> , 2001, 207-213, 85	

Examiner Signature	<i>Reevo</i>	Date Considered	<i>8/22/02</i>
--------------------	--------------	-----------------	----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number.

<sup>2</sup> Applicant is to place a check mark here if English language Translation attached.

RECEIVED

MAY 30 2002

#7

Please type a plus sign (+) inside this box → 

TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/028,547
				Filing Date	December 19, 2001
				First Named Inventor	Jay D. Kranzler
				Group Art Unit	1614
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	CYPR-023/01US

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office	Number	Kind Code (if known)			

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	<sup>2</sup>
N	D8	ARDID, et al., "Antidepressants and pain," <i>La Lettre de Pharmacologie</i> , 13:8, October 1993, 191-195.	
N	D9	NAGAOKA, et al., "Beneficial Effects of a Serotonin-Noradrenaline Reuptake Inhibitor on Fibromyalgia Syndrome: A Case Report," <i>Medicine and Drug Journal</i> , 37:10, October 1, 2001, 238-240.	

Examiner Signature	<i>R Cook</i>	Date Considered	<i>8/22/02</i>
--------------------	---------------	-----------------	----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup> Unique citation designation number.

<sup>2</sup> Applicant is to place a check mark here if English language Translation attached.